−67%
Marketing cost reduction
+375%
Target results increase
7 → 1
US oncology category rank
Massive Bio operates at the frontier of oncology trial matching, where every dollar of marketing spend has to do double duty — reaching patients and persuading institutions.
Using inMOLA Core, the team modeled the cost-to-conversion economics of every channel, identified where spend was being wasted, and reallocated budgets toward channels with structural advantages. In the working year, Massive Bio rose from 7th to 1st place among seven major companies in brand valuation within the cancer category in the U.S. market.
Within twelve months, marketing costs were reduced by 67% while target results increased by 375% — a structural step-change in performance efficiency, not a one-off campaign win.